HK1208460A1 - Protein kinase inhibitors - Google Patents

Protein kinase inhibitors Download PDF

Info

Publication number
HK1208460A1
HK1208460A1 HK15109229.7A HK15109229A HK1208460A1 HK 1208460 A1 HK1208460 A1 HK 1208460A1 HK 15109229 A HK15109229 A HK 15109229A HK 1208460 A1 HK1208460 A1 HK 1208460A1
Authority
HK
Hong Kong
Prior art keywords
protein kinase
kinase inhibitors
inhibitors
relates
present
Prior art date
Application number
HK15109229.7A
Other languages
English (en)
Chinese (zh)
Inventor
Alain Laurent
Yannick Rose
James B. Jaquith
Original Assignee
Gb005, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2779184A external-priority patent/CA2779184A1/en
Priority claimed from CA2813299A external-priority patent/CA2813299A1/en
Application filed by Gb005, Inc. filed Critical Gb005, Inc.
Publication of HK1208460A1 publication Critical patent/HK1208460A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15109229.7A 2012-05-31 2013-05-28 Protein kinase inhibitors HK1208460A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA2779184A CA2779184A1 (en) 2012-05-31 2012-05-31 Protein kinase inhibitors
CA2,779,184 2012-05-31
CA2,813,299 2013-04-17
CA2813299A CA2813299A1 (en) 2013-04-17 2013-04-17 Protein kinase inhibitors
PCT/CA2013/000513 WO2013177668A1 (en) 2012-05-31 2013-05-28 Protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1208460A1 true HK1208460A1 (en) 2016-03-04

Family

ID=49672221

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109229.7A HK1208460A1 (en) 2012-05-31 2013-05-28 Protein kinase inhibitors

Country Status (11)

Country Link
US (1) US9796716B2 (enExample)
EP (1) EP2855484A4 (enExample)
JP (1) JP6175495B2 (enExample)
KR (2) KR20190043648A (enExample)
CN (1) CN104379586B (enExample)
BR (1) BR112014029718A2 (enExample)
CA (1) CA2874211A1 (enExample)
HK (1) HK1208460A1 (enExample)
IN (1) IN2014MN02338A (enExample)
RU (1) RU2678767C2 (enExample)
WO (1) WO2013177668A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833867A1 (en) * 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
CA2834528A1 (en) * 2013-11-26 2015-05-26 Pharmascience Inc. Protein kinase inhibitors
RU2674701C2 (ru) * 2014-07-07 2018-12-12 Цзянсу Хэнжуй Медицин Ко., Лтд. Аминопиридазиноновые соединения в качестве ингибиторов протеинкиназы
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
US20180179210A1 (en) * 2015-05-27 2018-06-28 Pharmascience Inc. Inhibitors of the TEC Kinase Enzyme Family
US10927087B2 (en) 2015-12-07 2021-02-23 Dic Corporation Method for producing polymerizable compound
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
CN109369654A (zh) * 2018-11-20 2019-02-22 山东大学 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
JP2024544558A (ja) * 2021-11-15 2024-12-03 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｓｒｃ阻害剤としての化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
PT1212327E (pt) * 1999-09-17 2004-01-30 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos
SK3792002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Kinase inhibitors as therapeutic agents
SK13752001A3 (sk) * 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
AUPR392301A0 (en) 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
US20040248906A1 (en) * 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
EP2526934B1 (en) * 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
WO2011046954A1 (en) * 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
JP6139782B2 (ja) * 2013-05-21 2017-05-31 チャンスー メドリューション リミテッド 置換ピラゾロピリミジン化合物、及びその薬学的に許容される塩、並びにこれらの溶媒和物、立体異性体、及び互変異性体、並びにこれらを含む医薬組成物
CN103787839B (zh) 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 合成2,3,4,5,6-五氟苯酚的方法

Also Published As

Publication number Publication date
KR20190043648A (ko) 2019-04-26
JP2015518009A (ja) 2015-06-25
WO2013177668A1 (en) 2013-12-05
EP2855484A1 (en) 2015-04-08
KR101972990B1 (ko) 2019-04-26
US9796716B2 (en) 2017-10-24
IN2014MN02338A (enExample) 2015-08-14
BR112014029718A2 (pt) 2017-06-27
KR20150015527A (ko) 2015-02-10
CA2874211A1 (en) 2013-12-05
US20150191473A1 (en) 2015-07-09
RU2014145285A (ru) 2016-07-20
CN104379586A (zh) 2015-02-25
RU2678767C2 (ru) 2019-02-01
JP6175495B2 (ja) 2017-08-02
CN104379586B (zh) 2018-01-16
EP2855484A4 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
HK1208460A1 (en) Protein kinase inhibitors
HUS1900012I1 (hu) Vegyületek és készítmények protein-kináz inhibitorokként
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
WO2012158843A3 (en) Kinase inhibitors
HK1210696A1 (en) Irak inhibitors and uses thereof
IL252063A0 (en) dna-pk suppressors, preparations containing them and their uses
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
WO2012058211A3 (en) Quinazoline derivatives, compositions, and uses related thereto
WO2014011911A3 (en) Irak inhibitors and uses thereof
SMT202100425T1 (it) 2-ammino-n-(piperidin-1-il-piridin-3-il) pirazolo[1,5alpha]piirimidina-3-carbossiammide come inibitore di atr chinasi
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
HK1209768A1 (en) Antibodies to tau
EP3027026A4 (en) Aerosol tyrosine kinase inhibitor compounds and uses thereof
AP2015008381A0 (en) Bruton's tyrosine kinase inhibitors
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
EP2729464B8 (en) Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors
PH12013501922A1 (en) Protein kinase inhibitors
WO2014078268A3 (en) Anti-hemagglutinin antibodies and methods of use
EP3083559A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
ZA201409256B (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
IL227406A (en) Pyrimidine Gyrase and Topoisemarase Suppressors IV preparations containing them and their uses
WO2011106248A3 (en) Trimethoxyphenyl inhibitors of tyrosine kinase
HK1209726A1 (en) Protein kinase inhibitors
ZA201406777B (en) 3,5-diaminopyrazole kinase inhibitors
EP3046554A4 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF